Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies
OncLive,
The pipeline of new agents in gastrointestinal (GI) cancers is robust, with the emergence of several antibody-drug conjugates (AD…
The pipeline of new agents in gastrointestinal (GI) cancers is robust, with the emergence of several antibody-drug conjugates (AD…
Cathy Eng, MD Treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in an overall response rate (ORR) of 24.3% in…
A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam…
The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse…